Revance Therapeutics【RVNC】銘柄情報 | ADVFN

US Dollar vs Yen

ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。

登録

ホーム
投資
株式
アメリカ
NASDAQ
Revance Therapeutics Inc (RVNC) 銘柄情報

Revance Therapeutics Inc (RVNC)

3.65

0.00

(0.00%)

終了 3月11日 5:00AM

3.65

0.00

( 0.00% )

プレマーケット: 9:00AM

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

3.65

買値

3.84

売値

3.10

出来高

-

0.00 日の範囲 0.00

2.30 52 週間の範囲 6.65

前日終値

3.65

始値

-

時刻

最終取引時間

-

平均取引量 (3 か月)

1,720,710

財務取引量

-

VWAP

-

Form 15-12G - Securities registration termination [Section 12(g)]

Investors in Revance Therapeutics, Inc. Should Contact The Gross Law Firm Before March 4, 2025 to Discuss Your Rights - RVNC

Investors in Revance Therapeutics, Inc. Should Contact The Gross Law Firm Before March 4, 2025 to Discuss Your...

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	3.65	3.65	3.65	0	0	CS
4	0	0	3.65	3.65	3.65	0	0	CS
12	0.57	18.5064935065	3.08	3.7	3.03	1720710	3.43364425	CS
26	-2.92	-44.4444444444	6.57	6.59	3.01	2568273	4.38380361	CS
52	-2.65	-42.0634920635	6.3	6.65	2.3	2733204	4.7114846	CS
156	-12.88	-77.9189352692	16.53	37.98	2.3	1846758	12.19829081	CS
260	-15.9	-81.3299232737	19.55	37.98	2.3	1354483	13.96706843	CS

RVNC - Frequently Asked Questions (FAQ)

What is the current Revance Therapeutics share price?

The current share price of Revance Therapeutics is US$ 3.65

What is the 1 year trading range for Revance Therapeutics share price?

Revance Therapeutics has traded in the range of US$ 2.30 to US$ 6.65 during the past year

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
AWHAspira Womans Health Inc	US$ 0.3547 (79.14%)	98.12M
TSVT2seventy bio Inc	US$ 4.9312 (76.11%)	3.31M
ONDSOndas Holdings Inc	US$ 1.20 (65.06%)	13.48M
SNOASonoma Pharmaceuticals Inc	US$ 4.30 (54.12%)	26.32M
TNONTenon Medical Inc	US$ 1.85 (48.00%)	16.33M
MBXMBX Biosciences Inc	US$ 5.01 (-44.21%)	2
ARVNArvinas Inc	US$ 11.08 (-36.90%)	717.42k
XAGELongevity Health Holdings Inc	US$ 0.2301 (-28.09%)	1.06M
SPGCSacks Parente Golf Inc	US$ 0.1184 (-26.05%)	5.56M
SNCRSynchronoss Technologies Inc	US$ 6.01 (-22.45%)	4
AWHAspira Womans Health Inc	US$ 0.3547 (79.14%)	98.12M
SYRSSyros Pharmaceuticals Inc	US$ 0.1344 (46.72%)	92.03M
CUTRCutera Inc	US$ 0.1731 (34.71%)	60.6M
BHATBlue Hat Interactive Entertainment Technology	US$ 0.0413 (23.28%)	43.56M
TSLLDirexion Daily TSLA Bull 2X Trust ETF	US$ 7.40 (0.27%)	36.15M

biotech_researcher

biotech_researcher 2週前

How Med Spas Conquered America
https://www.bloomberg.com/news/articles/2025-02-19/med-spas-boom-with-botox-lip-filler-weight-loss-drugs-in-demand

AXRX4952

AXRX4952 4週前

glad I sold when my shares had a 6 in front of it... best of luck to you all. I feel for the RVNC sales force who has to pick themselves up and work for Crown - it's not a great place to be.

CosmeticMD

CosmeticMD 4週前

Good to see you want to continue your bagholder echo chamber even after the bag was taken away

vinmantoo

vinmantoo 1月前

If only we could be as wise as CosmeticMD, the king of gracious posting.

You mean the proven liar who whined people didn't trust a liar.

Ellington

Ellington 1月前

If only we could be as wise as CosmeticMD, the king of gracious posting.

PioneerUniverse8

PioneerUniverse8 1月前

reading some of my old posts... Boy was I wrong.

CosmeticMD

CosmeticMD 1月前

And this is what happens to ignorami who ignore actual real world experience. Enjoy your $3.65 a share (which is about 1/10 what I sold my Revance Shares for)

CosmeticMD

CosmeticMD 1月前

Naw, seeing patients all day, busier than ever. But good luck in the future. Maybe listen to those who actually use the product instead of some guy that bases his entire investment philosophy on a single study.

alertmeipp

alertmeipp 1月前

Goodbye, everyone—wishing you all the best in your future investments!

vinmantoo

vinmantoo 1月前

I'm sorry you lost your license to practice medicine..

That is what happens to an "MD" who lies and pretends. I didn't bother reading the comment of that proven liar.

biotech_researcher

biotech_researcher 1月前

I'm sorry you lost your license to practice medicine.. Good luck to you..

👍️ 2 💯 1

alertmeipp

alertmeipp 1月前

Had really high hope for the product, thought the turnaround would gain the traction and worst case would be a sale, but with higher price.

Management either corrupted or sucks

CosmeticMD

CosmeticMD 1月前

I'll miss all of you. Especially the ones who told me I was wrong when I said this was a crap product and a crap company a year and a half ago...

YY1000

FYI, I sold all my RVNC shares in a Fidelity Roth account at 3:57pm with a 3.65 limit (so I wouldn't have to worry about this account getting paid) and the order was filled at 3.66! Size was higher than a similar order for 50,000 shares on Schwab that was filled at 3.65. That is significantly better execution on Fidelity! The highest price I see in trades around this time is 3.655, so almost looks like Fidelity ate a couple hundred dollars on this transaction. Strange...

Now have to wait and see how long it takes until my remaining shares get paid.

YY1000

Answering my question here... there is a 0.0002674 exchange fee per share on the sale, so unless one gets at least 3.6503 execution, it is better to wait until closing tomorrow. As a retail investor I cannot specify a fractional cent limit.

I wonder if buyers that are paying 2.655 today (also there have been some trades at 2.66) could be shorts covering or closing other hedges, who if they had waited until tomorrow might have faced fees higher than 0.005 per share to close their positions.

Ellington

Ellington 1月前

And why is someone paying more than $3.65?

I sold all today.

YY1000

I don't know about biggest, but certainly my costliest investing mistake...
Any reason not to sell today? I have not tendered any shares and this way I get the money a day early...
Updating the previous version of this message, on 1000 share trades Schwab gives me 3.6505, but on 50,000 shares I got 3.6500, so I don't see a way to get a better price, even though several trades go through at 3.655...

vinmantoo

vinmantoo 1月前

RVNC was my biggest investing mistake ever. Daxxify is a great product, but management undercut the company's prospects again and again. C'est la vie.

Dew, I sold the rest of my RVNC shares on Monday. I didn't want to open my Schwab account and see RVNC listed among my holdings, even though it just advanced that outcome by a few days. Better luck next for both of us on our other investments.

valiano

valiano 1月前

Thanks for posting your thoughts all along, Dew. I'm sure you'll bounce back :)

Ellington

Ellington 1月前

Why is the bid-ask at 3.65-3.66, with more at the bid?

DewDiligence

DewDiligence 1月前

Crown-RVNC merger will close tomorrow (2/6/25):

https://www.sec.gov/Archives/edgar/data/1479290/000119312525020472/d814461dsc14d9a.htm

82% of RVNC shares tendered, exceeding the 50% threshold for completing the deal.

RVNC was my biggest investing mistake ever. Daxxify is a great product, but management undercut the company's prospects again and again. C'est la vie.

Emannow

Emannow 1月前

Allergan continues to lose market share in both toxin and filler!

Sadly, Foley blew all the RVNC’s cash with his terrible decisions and destroyed the company! Now Bill Meury from Crown Labs told me years ago, that Foley was a terrible person and idiot! Bill was right!!!

Global net revenues from the aesthetics portfolio were $1.298 billion, a decrease of 5.2 percent on a reported basis, or 4.4 percent on an operational basis.
Global Botox Cosmetic net revenues were $687 million, a decrease of 4.2 percent on a reported basis, or 3.4 percent on an operational basis.
Global Juvederm net revenues were $279 million, a decrease of 16.3 percent on a reported basis, or 15.1 percent on an operational basis.

IanFromSI

IanFromSI 1月前

If the deal is terminated without Crown Labs buying RVNC, then those who have not yet sold their shares will get whatever the market offers.

Worst case, given that Revance management has issued multiple going concern warnings, those still holding the shares may end up with zero dollars to show for it.

If crown labs gets at least 50% of the shares (plus one share), then it can force any remaining holders of its shares to sell at the tender price

DewDiligence

DewDiligence 1月前

If the deal goes through, shareholders who don't tender get the same payout as those who do tender, but it may take slightly longer to get paid.

Ellington

Ellington 1月前

I wonder if that's the end of the game.

There was something in the SEC document about a two-step process, such that people not tendering could conceivably lose out if the second step didn't happen.

DewDiligence

DewDiligence 1月前

Teoxane throws in the towel—will tender shares to Crown:

https://www.sec.gov/Archives/edgar/data/1479290/000095010325001086/xslSCHEDULE_13D_X01/primary_doc.xml

Teoxane was bluffing about wanting to acquire RVNC, IMO, but the bluff succeeded in getting Crown to pay an additional $0.55/sh.

MrMILL

What does that even mean? If I'm not mistaken, we are done here with them accepting Crowns deal at $3.65? I was hoping that TEOXANE would counter it back at $4.00 and Crown would walk. Foley is definitely in bed with Crown.

alertmeipp

alertmeipp 2月前

the buyout deal is terminated.

Maybe a bit selfish here, but that would be a nice outcome and I would happily buy back my shares if that happens.

DewDiligence

DewDiligence 2月前

RVNC accepts Crown’s $3.65/sh—tender_must_be_completed_by 2/7/25:

https://investors.revance.com/investors/Press-Releases/news-details/2025/Crown-Laboratories-and-Revance-Amend-the-AR-Merger-Agreement-to-Increase-Offer-Price-to-3.65-per-Share-and-Extend-Existing-Tender-Offer/default.aspx

If Crown does not obtain a majority of RVNC shares by 2/7/25, the buyout deal is terminated.

stocksrising

stocksrising 2月前

better than most of us who sold ALL ( some at $6.51 and $3.07ish).. only some friends and fam didn't sell/tender yet.. Crown not giving bod much time to decide, shotgun wedding it seems :)....will be interesting* if Teox comes back today with any filings( Sec, or RVNC) with higher bid, or at this point, who knows?????
actually don't care anymore with this drama show, just focusing on 3 other potential 5/10 baggers in 2025...
* for existing SH's

vinmantoo

vinmantoo 2月前

The Crown Proposal remains subject to formal consent and approval from both Crown’s Board of Directors and Revance’s Board. Crown indicated that the $3.65 offer expires at 4:10 p.m., Eastern Time, on January 17, 2025. The Revance Board will evaluate the Crown Proposal consistent with its duties.

The scumbags at Crown are giving RVNC only ONE day to consent. Come on Teoxane, beat that offer.

vinmantoo

vinmantoo 2月前

$3.65 is my guess, lmao …today!!

You can thank me for the price rise as I sold half my remaining shares yesterday just before close.

whoswho

whoswho 2月前

Item 8. Additional Information to be Furnished.

Item 8 (“Additional Information”) of the Schedule 14D-9 is hereby amended and supplemented by adding the following information set forth below after the last paragraph of the subsection entitled “Subsequent Events”:

On January 16, 2025, Crown provided to Revance non-binding proposed amendments to the A&R Merger Agreement, Equity Commitment Letter and Limited Guarantee (together, the “Crown Proposal”). The Crown Proposal contemplates the following material changes to the terms of the A&R Merger Agreement: (i) an increase in the Offer Price to $3.65 per share; (ii) an increase in the Company Termination Fee to $15,290,488.66; and (iii) an increase in the Parent Termination Fee to $22,935,732.99. The Crown Proposal remains subject to formal consent and approval from both Crown’s Board of Directors and Revance’s Board. Crown indicated that the $3.65 offer expires at 4:10 p.m., Eastern Time, on January 17, 2025. The Revance Board will evaluate the Crown Proposal consistent with its duties.

whoswho

whoswho 2月前

Thanks for the info!

so now the race is between $3.60 vs $3.65. LOL

anesthesia doc

anesthesia doc 2月前

Crown raised their offer to $3.65

whoswho

whoswho 2月前

Any news today? why the sudden jump to $3.60+?

stocksrising

stocksrising 2月前

$3.65 is my guess, lmao …today!!

MrMILL

Do you or anyone else have an opinion on the latest extension? Also, the number of shares tendered by shareholders appears very low, or am I not understanding the amount they need? I for one am holding my shares. I figure the worst case scenario is $3.10....

MeteoricChimera43

MeteoricChimera43 2月前

Pomerantz’s Law http://www.pomlaw.com/

They are the first and only Law firm to have already filed an actual case against RVNC and will likely be the lead in a Class Action. You don’t need to still have shares. As long as you owned shares sometime from February 2024 to December 6th, you qualify

stocksrising

stocksrising 2月前

Did you go with Josh? {Fruchter}..if so, I started to send docs but decided to just take the hit and move on ...good luck, we will all "win" something ( pennies perhaps) but will get more satisfaction for Fooley & Crew's loss !! GLTA

MeteoricChimera43

MeteoricChimera43 2月前

Read the new 8k today from Revance talking about considering Teoxane
proposal and Crowns letter to Revance basically acting like “take our offer or we will back out”. How Teoxanes offer isn’t vetted, with no proof that their financing is all committed, therefore not even a valid offer. Basically telling.Revance that they’re not gonna budge and they’re not gonna extend their tender offer termination for next week. I think we all know they’re full of shit and still want the deal and will easily pay 4 to 5 dollars a share to get it. It’ll be interesting to see how long this battle takes, and who comes out on top. Myself and two of my good friends who are large holders of RVNC we’re just named as lead, plaintiffs through one of the biggest law firms and the first firm to file actual suit against Revance last week

MeteoricChimera43

MeteoricChimera43 2月前

What are your guesses about how much Crown will raise their offer price to and when?

biotech_researcher

biotech_researcher 2月前

With the negative response by the market, the arbs are not engaged..

Tal10

Let the lawsuits against Teoxane begin! This has corruption written all over it.

soma2022

soma2022 2月前

I feel that Bill Meury (Chair of Crown and Hildred Capital Senior Adviser) will not want over 1 year of hard work and expense to slip away at just a $0.50/share higher price = $52M.

Background of Bill Meury: https://www.hildred.com/team/bill-meury
Allergan's Chief Commercial Officer from 2015 to 2020. Bill was with Actavis in 2014 and was instrumental along with Brent Saunders in blocking Valeant's hostile takeover of Allergan. Actavis then took on the Allergan name and was eventually acquired by Abbvie in 2019.
https://www.reuters.com/article/business/allergan-agrees-to-66-billion-actavis-offer-valeant-walks-idUSKCN0J00W7/

There are indications that Allergan looked at potentially acquiring Revance some 8 to 10 years ago. If these rumors are true, then Bill Meury would have been actively involved in those discussions. If this is the case, then Bill has been patiently stalking Revance waiting for an opportunity like this for almost 10 years.

There is a reasonably strong possibility that Crown will increase their offer price.

👍️ 3 💯 1

stocksrising

stocksrising 2月前

this offer wasn't shocking to me, anyway.. but needed the funds and loss to build positions in 3 other Bio's... good on you for still in game, we shall see how this drama plays out over coming days.. I think Anus( ANGUS, SORRY Still pissed about b.o.d's) is focused on Structure Thera and can give 2 sh*ts about shareholders :(
still, GLTA that own

soma2022

soma2022 2月前

Termination Fee. Revance may be required to pay the $13,373,000 termination fee to Crown if the A&R Merger Agreement is terminated under certain circumstances, including by Revance to accept a Superior Proposal. The Revance Board considered the risk that the amount of the termination fee would deter potential alternative acquisition proposals.

vinmantoo

vinmantoo 2月前

Teoxane SA Announces Superior Proposal to Acquire Revance
Therapeutics for $3.60 per Share in
Cash
09:03 : Monday 6 January 2025

I still have ~ 1/3 of my shares only because they were the ones not underwater and I was generating tax loss for 2024. I just never got around to the selling the rest as we entered 2025. While I am glad of a higher offer, it would take a counter offer to lessen my annoyance a bit. From the outside it looked like Teoxane torpedoed the $6.66 price so I need Crown or some other entity to start a bidding war.

MeteoricChimera43

MeteoricChimera43 2月前

Do we think Crown will bid higher? Does Crown already have the 60% threshold of shares to force their buyout and thus is just Texoxane trying to get a higher sale price for their 8% stake

stocksrising

stocksrising 2月前

Teoxane SA Announces Superior Proposal to Acquire Revance
Therapeutics for $3.60 per Share in
Cash
09:03 : Monday 6 January 2025

https://ih.advfn.com/p.php?pid=nmona&article=95199461&_gl=1*k8vpjc*_gcl_au*MjEwMzA0NjM5Ni4xNzM0Mjc3ODAz

Revance Therapeutics

Citigroup Global Markets...

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約